Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023

Aclaris Therapeutics, Inc.

2023-Q2 EPS reported -$0.84 revenue$4,397,000

Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.
Cash $210.8M, sufficient through 2025; includes $26.7M from ATM share sale in April 2023.
Zunsemetinib Phase 2b RA trial enrollment completed; topline data expected Q4 2023.
ATI-2138 Phase 1 MAD completed in healthy volunteers; data expected September 2023.
G&A expenses $8.3M include bad debt from EPI Health bankruptcy filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.